1. Home
  2. REGN vs NTES Comparison

REGN vs NTES Comparison

Compare REGN & NTES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$786.23

Market Cap

79.4B

Sector

Health Care

ML Signal

HOLD

Logo NetEase Inc.

NTES

NetEase Inc.

HOLD

Current Price

$117.37

Market Cap

81.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGN
NTES
Founded
1988
1997
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
79.4B
81.7B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
REGN
NTES
Price
$786.23
$117.37
Analyst Decision
Buy
Buy
Analyst Count
23
3
Target Price
$815.04
$160.00
AVG Volume (30 Days)
657.5K
883.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
0.49%
2.62%
EPS Growth
8.19
N/A
EPS
41.48
N/A
Revenue
$5,872,227,000.00
N/A
Revenue This Year
$11.69
$9.98
Revenue Next Year
$10.12
$8.35
P/E Ratio
$18.54
$79.88
Revenue Growth
20.82
N/A
52 Week Low
$476.49
$88.54
52 Week High
$821.11
$159.55

Technical Indicators

Market Signals
Indicator
REGN
NTES
Relative Strength Index (RSI) 53.95 37.92
Support Level $737.04 $103.23
Resistance Level $818.06 $135.02
Average True Range (ATR) 21.81 2.25
MACD -1.05 0.39
Stochastic Oscillator 55.37 63.93

Price Performance

Historical Comparison
REGN
NTES

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

About NTES NetEase Inc.

Founded in the late 1990s as an internet portal, NetEase has transformed into a leading force in the second-largest online game company gaming in China. While its initial success was built upon the massively multiplayer online role-playing game Fantasy Westward Journey, NetEase has expanded its portfolio with captivating franchises that resonate with both domestic and international players. Over the past decade, the company has created titles such as Justice, Identity V, Naraka: Bladepoint, and Eggy Party, all of which maintain significant player bases today. Beyond in-house development, the company also collaborates with likes of Microsoft and Marvel to create and publish games based on renowned IPs, including World of Warcraft, Diablo Immortal, and Marvel Rivals.

Share on Social Networks: